Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells.

ABSTRACT:

Background

Systems biology leveraging multi-OMICs technologies, is rapidly advancing development of precision therapies and matching patients to targeted therapies, leading to improved responses. A new pillar of precision oncology lies in the power of chemogenomics to discover drugs that sensitizes malignant cells to other therapies. Here, we test a chemogenomic approach using epigenomic inhibitors (epidrugs) to reset patterns of gene expression driving the malignant behavior of pancreatic tumors.

Methods

We tested a targeted library of ten epidrugs targeting regulators of enhancers and super-enhancers on reprogramming gene expression networks in seventeen patient-derived primary pancreatic cancer cell cultures (PDPCCs), of both basal and classical subtypes. We subsequently

SUBMITTER: Fraunhoffer NA 

PROVIDER: S-EPMC10189188 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature